# Porcine Trypsinogen (Sus scrofa domesticus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/porcine-trypsinogen
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Enzyme
**Also Known As:** Pig trypsinogen, Porcine pancreatic trypsinogen, Swine trypsinogen, Pancreatic trypsinogen (porcine), Trypsinogen (Sus scrofa), PRSS1 (porcine), Porcine protease zymogen

## Overview

Porcine trypsinogen is a zymogen precursor to the serine protease trypsin, derived from the pancreas of domestic pigs (Sus scrofa domesticus). When activated by enterokinase in the duodenum, it cleaves peptide bonds at lysine and arginine residues, enabling efficient dietary protein [digestion](/ingredients/condition/gut-health).

## Health Benefits

• Supports protein [digestion](/ingredients/condition/gut-health) in pancreatic insufficiency (moderate evidence from pancreatic enzyme studies)
• Aids nutrient absorption in cystic fibrosis patients (moderate evidence from clinical use)
• Helps manage digestive symptoms in exocrine pancreatic disorders (moderate evidence from pancreatin formulations)
• Facilitates breakdown of dietary proteins at lysine/arginine residues (established mechanism)
• Provides digestive support without significant adverse effects in long-term use (safety data from post-marketing surveillance)

## Mechanism of Action

Porcine trypsinogen is activated to trypsin by the intestinal brush-border enzyme enterokinase (enteropeptidase), which cleaves the N-terminal trypsinogen activation peptide (TAP). Active trypsin functions as a serine protease, hydrolyzing peptide bonds on the C-terminal side of lysine and arginine residues via a catalytic triad of serine, histidine, and aspartate. Trypsin also autocatalytically activates additional trypsinogen molecules and downstream zymogens including chymotrypsinogen, proelastase, and procarboxypeptidases, amplifying the full [digestive enzyme](/ingredients/condition/gut-health) cascade.

## Clinical Summary

Porcine trypsinogen is most extensively studied as part of porcine pancreatic enzyme replacement therapy (PERT) formulations, including pancrelipase, in randomized controlled trials involving patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis or cystic fibrosis, with sample sizes typically ranging from 30 to 150 patients. A 2011 Cochrane review of PERT in cystic fibrosis confirmed significant improvements in fat and protein absorption coefficients, though individual trypsinogen-isolated trials are limited. In EPI patients, enteric-coated enzyme formulations containing trypsinogen reduced fecal nitrogen excretion by approximately 30–50% compared to placebo in several phase III trials. Evidence for isolated porcine trypsinogen supplementation outside combination PERT is sparse, and most clinical benefit data are extrapolated from multi-enzyme pancreatic preparations.

## Nutritional Profile

Porcine Trypsinogen is a pure enzyme protein (zymogen precursor to trypsin) derived from porcine pancreatic tissue. Macronutrient composition: ~100% protein by dry weight, with negligible fat and carbohydrate content. Molecular weight: approximately 24,000 Da (24 kDa) as a single-chain polypeptide of 229 amino acids. Amino acid composition is rich in lysine and arginine residues (the specific cleavage recognition sites), with a notable disulfide bond network (6 cysteine residues forming 3 disulfide bridges) contributing to structural stability. Contains a catalytic triad of histidine, aspartate, and serine residues at the active site upon activation to trypsin. Micronutrient content: Contains a single calcium ion (Ca²⁺) binding site per molecule, which stabilizes the enzyme structure and contributes to autolysis resistance; calcium concentration functionally relevant at approximately 1 mol Ca²⁺ per mol enzyme. Zinc is not intrinsically bound but activation environment may involve divalent cations. Bioactive compounds: The zymogen itself is inactive until cleaved by enterokinase (enteropeptidase) at the Lys6-Ile7 bond, releasing the 6-residue activation peptide (Val-Asp-Asp-Asp-Asp-Lys) and yielding active trypsin. Specific activity of activated form: approximately 10,000–15,000 BAEE units/mg protein (N-benzoyl-L-arginine ethyl ester assay). Bioavailability note: As an orally administered enzyme, trypsinogen is subject to gastric acid degradation; pharmaceutical preparations typically use enteric coating to ensure delivery to the duodenum where activation and proteolytic function occur. Not a meaningful dietary source of vitamins or minerals at therapeutic doses (typical dose range 10,000–40,000 USP units per meal in pancreatic enzyme replacement therapy formulations).

## Dosage & Preparation

No clinically studied dosages exist for isolated porcine trypsinogen. Within pancreatin formulations: 300 mg pancreatin contains proteases (1,000 PhEur units including trypsin), lipase (25,000 PhEur units), and amylase (18,000 PhEur units), dosed with meals. High doses in CF patients rarely linked to fibrosing colonopathy. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Porcine trypsinogen and trypsin-containing formulations are generally well tolerated, with the most common adverse effects being gastrointestinal in nature, including abdominal pain, nausea, diarrhea, and flatulence reported in 5–15% of users in clinical trials. High-dose pancreatic enzyme therapy has been associated with fibrosing colonopathy, particularly in pediatric cystic fibrosis patients receiving doses exceeding 10,000 lipase units/kg/day, necessitating dose monitoring. Porcine-derived products are contraindicated in individuals with confirmed pork allergies and should be used cautiously in those with a history of gout or hyperuricemia, as purine content may elevate uric acid levels. Safety data in pregnancy and lactation are insufficient; use should only occur under direct physician supervision, and porcine trypsinogen may theoretically potentiate the absorption of orally administered drugs by altering gut proteolytic activity.

## Scientific Research

Clinical evidence is indirect, primarily from studies on porcine pancreatic enzyme supplements containing trypsinogen/trypsin. One cross-sectional study (n=41 CF patients, n=12 controls) found 50-96% of CF patients developed IgG antibodies to porcine trypsin (mean 50.6 ng/ml), indicating immunogenicity without clinical harm (PMID: 1946313). Safety reviews of pancrelipase products and infant formula studies showed no significant adverse effects.

## Historical & Cultural Context

No evidence of traditional medicinal use exists. Porcine trypsinogen/pancreatic enzymes are modern pharmaceutical and food products, commercially available for decades primarily for treating exocrine pancreatic insufficiency in cystic fibrosis patients.

## Synergistic Combinations

Lipase, Amylase, Pancrelipase, Enteric coating agents, Digestive bitters

## Frequently Asked Questions

### What is porcine trypsinogen and how does it differ from trypsin?

Porcine trypsinogen is the inactive zymogen form of trypsin, secreted by pig pancreatic acinar cells and requiring cleavage by enterokinase to become catalytically active trypsin. This precursor form is intentionally inactive to prevent autodigestion of pancreatic tissue; once it reaches the duodenum, enterokinase removes an 8-amino-acid activation peptide, yielding functional trypsin capable of hydrolyzing dietary proteins at arginine and lysine residues.

### Who should take porcine trypsinogen supplements?

Porcine trypsinogen is primarily indicated for individuals with exocrine pancreatic insufficiency (EPI), a condition where the pancreas produces insufficient digestive enzymes, as seen in chronic pancreatitis, cystic fibrosis, and post-pancreatectomy states. It is typically administered as part of standardized pancreatic enzyme replacement therapy (PERT) under medical supervision, with dosing titrated to fat absorption and symptom response rather than used as an over-the-counter general digestive aid.

### What is the typical dosage of porcine trypsinogen in pancreatic enzyme formulations?

In pharmaceutical-grade pancreatic enzyme replacement products such as pancrelipase, trypsin activity is standardized alongside lipase and amylase activity; typical adult dosing provides 25,000–80,000 USP units of lipase per meal, with trypsin content proportionally included per the enzyme ratio in pancreatin. The American Pancreatic Association recommends starting at 25,000–40,000 lipase units per meal and titrating upward based on clinical response, with pediatric dosing in cystic fibrosis capped at 10,000 lipase units/kg/day to mitigate fibrosing colonopathy risk.

### Can porcine trypsinogen cause allergic reactions in people who avoid pork?

Yes, because porcine trypsinogen is derived from the pancreatic tissue of domestic pigs, individuals with IgE-mediated pork allergies or documented hypersensitivity to porcine proteins face a risk of allergic reactions ranging from urticaria to anaphylaxis. Patients with pork-cat syndrome, driven by cross-reactivity between porcine serum albumin and cat albumin, should also exercise caution; clinicians should screen for pork and alpha-gal sensitization before initiating porcine-derived enzyme therapy.

### Is porcine trypsinogen effective for general bloating and protein digestion in healthy people?

Evidence specifically supporting porcine trypsinogen use for protein digestion enhancement in otherwise healthy individuals is lacking, as clinical research has focused almost exclusively on patients with confirmed EPI or cystic fibrosis. In healthy adults, endogenous trypsinogen production is typically sufficient for normal protein digestion, and supplemental proteases have not demonstrated significant reductions in bloating or improved protein absorption in well-designed randomized trials in this population; enzyme blends containing bromelain or papain have more available (though still limited) data for healthy users.

### Does porcine trypsinogen work better when taken with meals or on an empty stomach?

Porcine trypsinogen should be taken with meals to be most effective, as it needs to mix with food in the stomach and small intestine to break down dietary proteins. Taking it on an empty stomach reduces its therapeutic benefit and may cause stomach irritation. Most clinical protocols recommend dosing at the beginning of each main meal for optimal protein digestion support.

### Are there any drug interactions between porcine trypsinogen and common medications?

Porcine trypsinogen has minimal direct drug interactions, but antacids and proton pump inhibitors (PPIs) that reduce stomach acid may reduce its effectiveness by creating an overly alkaline environment. Iron supplements should not be taken simultaneously, as pancreatic enzymes may interfere with iron absorption. Consult a healthcare provider before combining porcine trypsinogen with medications, especially anticoagulants or those affecting digestive pH.

### What does the clinical evidence say about porcine trypsinogen's effectiveness for pancreatic insufficiency?

Clinical studies demonstrate moderate to strong evidence that porcine trypsinogen, as part of pancreatin formulations, improves fat and protein absorption in patients with exocrine pancreatic insufficiency and cystic fibrosis. Most research shows measurable improvements in stool elasticity, nutrient absorption markers, and digestive symptom relief when dosed appropriately. However, individual response varies based on the degree of pancreatic enzyme deficiency and the enteropeptidase activity of the intestine.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*